Kevin Joseph Fitzgerald Sells 1,198 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,198 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $243.00 on Friday. The stock has a fifty day moving average price of $159.86 and a two-hundred day moving average price of $164.73. The stock has a market capitalization of $30.74 billion, a price-to-earnings ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. The company’s revenue was up 54.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.40) EPS. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.75 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after buying an additional 50,366 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after buying an additional 364,021 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after buying an additional 201,784 shares in the last quarter. Capital International Investors increased its position in shares of Alnylam Pharmaceuticals by 1.8% in the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after buying an additional 64,560 shares in the last quarter. Finally, Capital Research Global Investors increased its position in shares of Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent analyst reports. Evercore ISI increased their price target on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Needham & Company LLC increased their price objective on Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a report on Monday, June 24th. UBS Group increased their price objective on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $247.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.